Please assess the completion status of the following clinical trial:

Trial Title: Study of TAK-816 in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female infants aged ≥3 and \<7 months (excluding hospitalized infants).~2. Infants whose legal acceptable representatives have given informed consent to the study prior to enrollment.~3. Infants whose parents or legal guardians have agreed to cooperate with the investigator during the study period.~Exclusion Criteria:~1. Any serious acute illness.~2. Any underlying cardiovascular, renal, hepatic, or hematologic disease, and/or developmental disorder.~3. History of possible Haemophilus influenzae type b (Hib) infection.~4. History of possible pertussis, diphtheria or tetanus infection.~5. Previously diagnosed immunodeficiency.~6. A documented history of anaphylaxis to any ingredient of the investigational products (TAK-816, ActHIB or DPT-TAKEDA).~7. A history of convulsions.~8. Previous administration of another Hib vaccine.~9. Previous administration of any other vaccine containing any of the components of polio, diphtheria, pertussis, or tetanus.~10. Treatment with any live vaccine during the 27 days before the first dose of TAK-816 or with any inactivated vaccine during the 6 days before dosing.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- TAK-816 (Type: EXPERIMENTAL): None
- ActHIB (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).